Cancer cells destroyed with dinosaur extinction metal

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international collaboration between the University of Warwick and Sun Yat-Sen University in China. Researchers from the Professor Sadler and Professor O’Connor groups in Warwick's Department of Chemistry and Professor Hui Chao's group at Sun Yat-Sen have demonstrated that iridium - the world's second densest metal - can be used to kill cancer cells by filling them with deadly version of oxygen, without harming healthy tissue.

The researchers created a compound of iridium and organic material, which can be directly targeted towards cancerous cells, transferring energy to the cells to turn the oxygen (O2) inside them into singlet oxygen, which is poisonous and kills the cell - without harming any healthy tissue.

The process is triggered by shining visible laser light through the skin onto the cancerous area – this reaches the light-reactive coating of the compound, and activates the metal to start filling the cancer with singlet oxygen.

The researchers found that after attacking a model tumour of lung cancer cells, grown by the researchers in the laboratory to form a tumour-like sphere, with red laser light (which can penetrate deeply through the skin), the activated organic-iridium compound had penetrated and infused into every layer of the tumour to kill it - demonstrating how effective and far-reaching this treatment is.

They also proved that the method is safe to healthy cells by conducting the treatment on non-cancerous tissue and finding it had no effect.

Furthermore, the researchers used state-of-the-art ultra-high resolution mass spectrometry to gain an unprecedented view of the individual proteins within the cancer cells - allowing them to determine precisely which proteins are attacked by the organic-iridium compound.

After vigorously analysing huge amounts of data - thousands of proteins from the model cancer cells, they concluded that the iridium compound had damaged the proteins for heat shock stress, and glucose metabolism, both known as key molecules in cancer.

The University of Warwick has the UK's most advanced laboratory for this type of highly advanced mass spectrometry, and is a world-class centre of analytical science.

Co-author Cookson Chiu is a postgraduate researcher in Warwick’s Department of Chemistry, funded by the Engineering and Physical Sciences Research Council and Bruker. He commented: "This project is a leap forward in understanding how these new iridium-based anti-cancer compounds are attacking cancer cells, introducing different mechanisms of action, to get around the resistance issue and tackle cancer from a different angle."

Dr Pingyu Zhang and Dr Huaiyi Huang are Royal Society Newton International Fellows in Warwick's Department of Chemistry. Dr Zhang added: "Our innovative approach to tackle cancer involving targeting important cellular proteins can lead to novel drugs with new mechanisms of action. These are urgently needed. In addition, research links between UK and Chinese academics will not only lead to lasting collaborations, but also have potential to open up the translation of new drugs into the clinic as a UK-China joint development."

Peter O'Connor, Professor of Analytical Chemistry at Warwick, noted: "Remarkable advances in modern mass spectrometry now allow us to analyse complex mixtures of proteins in cancer cells and pinpoint drug targets, on instruments that are sensitive enough to weigh even a single electron!"

Professor Peter Sadler is excited about where this work can lead. He said: "The precious metal platinum is already used in more than 50% of cancer chemotherapies. The potential of other precious metals such as iridium to provide new targeted drugs which attack cancer cells in completely new ways and combat resistance, and which can be used safely with the minimum of side-effects, is now being explored.

"International collaborations can greatly hasten progress. It's certainly now time to try to make good medical use of the iridium delivered to us by an asteroid 66 million years ago!"

Photochemotherapy - using laser light to target cancer - is fast emerging as a viable, effective and non-invasive treatment. Patients are becoming increasingly resistant to traditional therapies, so it is vital to establish new pathways like this for fighting the disease.

Iridium was first discovered in 1803, and its name comes from the Latin for 'rainbow'. From the same family as platinum, it is hard, brittle, and is the world’s most corrosion-resistant metal. Yellow in colour, its melting point is more than 2400° Celsius.

The metal is rare on Earth, but is abundant in meteoroids - and large amounts of iridium have been discovered in the Earth's crust from around 66 million years ago, leading to the theory that it came to this planet with an asteroid which caused the extinction of the dinosaurs.

Zhang P, Chiu CKC, Huang H, Lam YPY, Habtemariam A, Malcomson T, Paterson MJ, Clarkson GJ, O'Connor PB, Chao H, Sadler PJ.
Organoiridium Photosensitizers Induce Specific Oxidative Attack on Proteins within Cancer Cells.
Angew Chem Int Ed Engl. 2017 Oct 19. doi: 10.1002/anie.201709082.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS™ …

The Bristol-Myers Squibb-Pfizer Alliance will present 15 Eliquis® (apixaban) posters at the ESC Congress 2018 held in Munich, Germany, August 25-29, 2018. Nine of the pos...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...